Backed by NEA and Norwest.
About the role
If you’re passionate about advancing innovative treatments for patients and shaping the future of precision peptide therapeutics, this is your chance to make a real impact alongside a fast-paced, growing, mission-driven team. To learn more, visit our website mbxbio.com and follow us on LinkedIn .
What they're looking for
- Provide clinical and scientific oversight of clinical study execution, from start-up to close-out and results reporting
- Develop a clinical study execution plan in collaboration with cross-functional study leads
- Share the responsibility for establishing and maintaining regular cross-functional study team meetings with the study Clinical Operations Lead
- Contribute to the selection and management of study vendors, including but not limited to CROs, central laboratories/imaging, clinical sites, EDC, IRT, TMF, etc
- Train internal and/or external study team members on medical and scientific aspects of the clinical study at SIVs and at other applicable forums
- Work closely with the Study Medical Lead and Director/Senior Director of Clinical Development to report clinical study progress and ensure timely communication of any identified medical or operational issues
More about this role
Working with Us
MBX Biosciences is a clinical-stage biopharmaceutical company headquartered in Carmel, Indiana, with a secondary office in Burlington, MA. Our mission is to transform the lives of people impacted by endocrine and metabolic disorders through our novel precision peptides.
Leveraging our proprietary Precision Endocrine Peptides (PEPs)™ platform, we are pioneering technology designed to overcome key limitations of existing therapies and enhance efficacy, tolerability, safety and convenience. Our team is advancing a pipeline of novel candidates with clinically validated targets, established endpoints for regulatory approval, and strong market potential.
Our pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism, currently preparing for Phase 3 development, and a growing obesity portfolio that includes MBX 4291 in Phase 1 development, MBX 5765, a next-generation amycretin prodrug designed for once-monthly-dosing, as well as MBX 6180, a GLP/GIP/GCGR triple agonist prodrug for once monthly dosing; all of which optimize our PEP platform.
If you’re passionate about advancing innovative treatments for patients and shaping the future of...
Browse similar: Startup jobs